We currently estimate that our cash, cash equivalents and marketable securities as of March 31, 2020 will be sufficient to fund our operations into the thirdquarter of 2022. (Seite 18)
Sind sowieso ein paar schöne Passagen dabei: Additionally, we are advancing our novel research platform targeting the Sec61 translocon and the protein secretion pathway to discover and develop smallmolecule therapeutics targeting oncology indications. Our first clinical candidate in this program, KZR-261, has demonstrated broad anti-tumor activity inpreclinical models of both solid and hematologic malignancies. KZR-261 is undergoing laboratory studies and manufacturing activities in support of aninvestigational new drug, or IND, application, which we anticipate submitting to the U.S. Food and Drug Administration, or FDA, in the first quarter of2021 for a Phase 1 clinical trial in solid tumors. We believe this discovery platform has the potential to yield oral small molecule candidates that, ifsuccessfully developed and approved, could serve as alternatives to currently marketed biologic therapeutics to act as cytotoxic anti-cancer agents or toblock the secretion of novel targets of interest in immuno-oncology or inflammation.
Thread abonnieren
